Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS022 vs Trastuzumab in HER2+ Breast Cancer
NCT06107790Phase 3Completed
- Sponsor
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Start
- May 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of HS022 in HER2-positive breast cancer, sponsored by Zhejiang Hisun Pharmaceutical Co., Ltd.. Started May 2018; status: completed.
02
Drugs
HS022
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06107790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06107790.